

Feelnor®

Trimetazidine Dihydrochloride tablet

Presentation

Feelnor® 35 MR tablet: Each modified release tablet contains Trimetazidine Dihydrochloride BP 35 mg.

Description

Trimetazidine is a unique antianginal and anti-ischaemic agent that display anti-ischaemic effects without inducing haemodynamic changes and improves the status of the ischaemic myocardium. The drug exerts its antianginal effects through a direct cytoprotective action on the myocardium, thereby avoiding the side-effects of impaired left ventricular function, excessive peripheral vasodilation and other disadvantages associated with the use of other antianginal agents.

Indications and uses

Trimetazidine 35 mg MR is indicated for-

- Long-term treatment of angina pectoris

Dosage and administration

One 35 mg MR tablet twice daily at mealtimes in the morning and evening.

Side-effects

Trimetazidine is safe and well tolerated. The most commonly side effects are gastric discomfort, nausea, headache and vertigo. However, the side effects are mild and non-specific.

Contraindications

Hypersensitivity to Trimetazidine Dihydrochloride.

Drug interactions

No drug interactions have so far been reported. In particular, no interactions of Trimetazidine with beta-blockers, calcium antagonists, nitrates, heparin, hypolipidemic agents or digitalis have been reported.

Use in pregnancy and lactation

Pregnancy: Studies in animals have not demonstrated a teratogenic effect. However, in the absence of clinical data and for safety reasons, prescription should be avoided during pregnancy.

Nursing Mothers: There is no information on the secretion of Trimetazidine into breast milk. However, breast feeding should be discontinued if the use of Trimetazidine is considered essential.

Pediatric use

Safety and efficacy in children have not been established with Trimetazidine.

Storage

Do not store above 30 °C. Keep away from light and out of the reach of children.

Commercial pack

Feelnor® 35 MR: Each box contains 3 blister strips of 10 tablets.

Manufactured by
 **Incepta Pharmaceuticals Ltd**
Savar, Dhaka, Bangladesh
© Registered Trademark

FEM

V.N.01